Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2023-02-23 00:00:00 ET · period of report 2023-02-22 · accession 0000899243-23-006004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-23 | 2023-02-22 | CGEM | AHMED NADIM | Pres, CEO, Dir | A - Grant | $0.00 | +109.0K | 118.7K | +1,123% | $0 |
| D | 2023-02-23 | 2023-02-22 | CGEM | AHMED NADIM | Pres, CEO, Dir | A - Grant | $0.00 | +211.0K | 211.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-22 | A | A | 109,000 | $0.00 | 118,710 | D | — | — | (F1) The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-22 | A | A | 211,000 | $0.00 | 211,000 | D | $11.03 · — to 2033-02-21 | 211,000 Common Stock | (F2) The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. |